Genmab, Immatics in bispecific immunotherapy deal

Immatics Biotechnologies GmbH (Tuebingen, Germany) granted Genmab A/S (CSE:GEN; Pink:GMXAY) exclusive, worldwide rights to develop bispecific, T cell-engaging immunotherapies against three targets to treat multiple cancer

Read the full 262 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE